$XENE

Xenon Pharmaceuticals Inc. (XENE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 xene-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Xenon Reports Q2 2026 Financial Results and Provides Business Update • NDA submission for azetukalner on track for Q3 2026 following pre-NDA meeting with FDA • Phase 3 X-TOLE3 study in FOS and X-ACKT study in PGTCS continue t

The article says Canada’s biotech sector has seen a strong 12-month run, with listed companies raising $2.4 billion on public markets and excluding Apotex’s $1.5 billion June IPO. It highlights several Canadian biotechs, especially AbCellera Biologics, which plans to report key human efficacy results this quarter for a menopause hot-flash treatment. It also notes foreign investors dominate funding.

VANCOUVER, BC and BOSTON, MA, July 30, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced it will report its second quarter 2026 financial results and provide a business update after the close of U.S. financial markets on Thursday, August 6, 2026.

Xenon Pharmaceuticals (Nasdaq: XENE) said it granted inducement equity to four new non-officer employees effective July 1, 2026: 20,200 share options and 11,850 RSUs. Options have a $60.30 exercise price (July 1 close) and vest over four years; RSUs vest 25% annually over four years, subject to continued service, per Nasdaq Rule 5635(c)(4).

Xenon Pharmaceuticals' azetukalner demonstrated a significant reduction in monthly seizure frequency, with a 53.2% decrease in the 25 mg group during its Phase 3 X-TOLE2 study. The positive trial results, presented at the American Academy of Neurology Annual Meeting, have led to a 70% surge in the company's stock over the past year and raised approximately $747.5 million in a recent public offering, extending its cash runway. Xenon plans to submit a New Drug Application to the FDA in Q3 2026 for azetukalner, a KV7 potassium channel opener.

This article provides a financial overview of Xenon Pharmaceuticals Inc (XENE), detailing its profitability margins and comparing them to competitors TGTX and RYTM. It highlights XENE's impressive 100.00% gross margin but notes negative operating and net margins. The article also mentions the company's market capitalization and Return on Equity.

Traders bought a significantly high volume of put options on Xenon Pharmaceuticals (NASDAQ:XENE) on Wednesday, indicating bearish sentiment or hedging. This comes amidst notable insider selling by the CEO and a miss on recent quarterly EPS, despite analysts maintaining a "Buy" rating and raising price targets. The company, a clinical-stage biopharmaceutical firm, is focused on developing drugs targeting ion channels for neurological and pain disorders.

JPMorgan has reiterated an Overweight rating on Xenon Pharmaceuticals (NASDAQ:XENE) with a price target of $62.00, suggesting a significant upside. The positive outlook is primarily based on the anticipated topline data release in early 2026 for its phase 3 X-TOLE2 trial, evaluating azetukalner for focal onset seizures. This aligns with a broader "Strong Buy" consensus among analysts, with Cantor Fitzgerald also raising its price target on Xenon due to a strong pipeline beyond seizure treatments.

VANCOUVER, British Columbia and BOSTON, MA, Nov. 25, 2025 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( Nasdaq: XENE ) , a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in ...

VANCOUVER, British Columbia and BOSTON, Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) , a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, ...